Tango Therapeutics (TNGX) vs Xenon Pharmaceuticals (XENE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Tango Therapeutics (TNGX) has outperformed Xenon Pharmaceuticals (XENE) over the past year, gaining 226.6% versus a loss of 7.9%. Over five years, TNGX leads with a +60.9% price change compared with +7.4% for XENE. Tango Therapeutics is the larger company by market cap ($3.97 billion vs $3.52 billion), about 1.1 times the size.
Tango Therapeutics converts more of its revenue into profit, with a net margin of -162.9% versus -4612.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TNGX | XENE |
|---|---|---|
| Share price | $23.52 | $36.36 |
| Market cap | $3.97B | $3.52B |
| 1-day change | +4.21% | +0.54% |
| YTD return | +154.74% | -19.32% |
| 1-year return | +226.63% | -7.87% |
| 5-year return | +60.87% | +7.43% |
| EPS (TTM) | $-0.85 | $-4.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $62.38M | $7.50M |
| Revenue growth (YoY) | +48.29% | — |
| Net income (latest FY) | $-101.59M | $-345.91M |
| Operating margin | -178.39% | -4974.27% |
| Net margin | -162.85% | -4612.13% |
| 52-week high | $34.39 | $72.66 |
| 52-week low | $6.69 | $35.06 |
| Distance from 52-week high | -31.61% | -49.97% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +92.09% | +101.82% |
| Average volume | 2.65M | 1.42M |
| Shares outstanding | 168.61M | 96.84M |
| Employees | 137 | 358 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TNGX has outperformed XENE by 234.5 percentage points over the past year.
- Tango Therapeutics is more profitable, keeping -162.9 cents of every revenue dollar as net income versus -4612.1 cents for Xenon Pharmaceuticals.
About Tango Therapeutics
TNGX stock →Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 137 employees
About Xenon Pharmaceuticals
XENE stock →Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression.
Health Care · Biotechnology: Pharmaceutical Preparations · 358 employees
TNGX vs XENE FAQ
Which is bigger, Tango Therapeutics or Xenon Pharmaceuticals?
Tango Therapeutics (TNGX) is larger, with a market capitalization of $3.97B compared with $3.52B for Xenon Pharmaceuticals (XENE).
Which stock has performed better over the past year, TNGX or XENE?
TNGX returned +226.63% over the past 12 months, compared with -7.87% for XENE (price return, excluding dividends). Past performance does not predict future results.
Are Tango Therapeutics and Xenon Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.